Back to top
more

Theratechnologies (THTX)

(Delayed Data from NSDQ)

$1.55 USD

1.55
43,484

-0.02 (-0.96%)

Updated Jul 23, 2024 03:59 PM ET

After-Market: $1.54 -0.01 (-0.32%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (82 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for THTX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for Theratechnologies Inc falls in the month of November.

All items in Millions except Per Share data.

11/30/2023 11/30/2022 11/30/2021 11/30/2020 11/30/2019
Assets          
Cash & Equivalents 40 33 40 21 41
Receivables 14 12 11 13 10
Notes Receivable 0 0 0 0 0
Inventories 6 20 29 25 21
Other Current Assets 3 8 11 6 5
Total Current Assets 63 73 92 65 76
Net Property & Equipment 1 1 1 1 1
Investments & Advances 0 0 0 0 1
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 2 1 0 0
Intangibles 13 15 21 25 27
Deposits & Other Assets 0 0 2 7 12
Total Assets 78 93 119 100 118
Liabilities & Shareholders Equity 11/30/2023 11/30/2022 11/30/2021 11/30/2020 11/30/2019
Notes Payable 0 0 0 0 0
Accounts Payable 28 41 40 35 31
Current Portion Long-Term Debt 7 65 0 5 3
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 0 0 0 0 0
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 11 8 4 2 3
Total Current Liabilities 47 114 45 42 37
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 0 0 0 0
Convertible Debt 0 0 54 52 51
Long-Term Debt 51 0 0 0 5
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 0 0 0 0 0
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 99 116 101 97 93
Shareholders Equity 11/30/2023 11/30/2022 11/30/2021 11/30/2020 11/30/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 364 339 336 287 287
Capital Surplus 23 19 13 12 11
Retained Earnings -409 -383 -335 -300 -277
Other Equity 1 3 4 4 4
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity -21 -23 18 3 25
Total Liabilities & Shareholder's Equity 78 93 119 100 118
Total Common Equity -21 -23 18 3 25
Shares Outstanding 45.90 24.20 23.70 19.20 19.20
Book Value Per Share -0.45 -0.93 0.75 0.17 1.29

Fiscal Year End for Theratechnologies Inc falls in the month of November.

All items in Millions except Per Share data.

5/31/2024 2/29/2024 11/30/2023 8/31/2023 5/31/2023
Assets          
Cash & Equivalents 36 38 40 23 25
Receivables 14 11 14 9 14
Notes Receivable NA 0 0 0 0
Inventories 6 6 6 7 9
Other Current Assets 2 3 3 2 3
Total Current Assets 57 58 63 41 51
Net Property & Equipment 0 1 1 1 1
Investments & Advances NA 0 0 0 0
Other Non-Current Assets NA 0 0 0 0
Deferred Charges 0 0 0 1 2
Intangibles 12 12 13 13 14
Deposits & Other Assets NA 0 0 0 0
Total Assets 70 72 78 57 69
Liabilities & Shareholders Equity 5/31/2024 2/29/2024 11/30/2023 8/31/2023 5/31/2023
Notes Payable NA 0 0 0 0
Accounts Payable 26 30 28 30 34
Current Portion Long-Term Debt 17 12 7 57 27
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 0 0 0 0
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities 8 8 11 10 10
Total Current Liabilities 52 50 47 98 71
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 0 0 0 0
Convertible Debt NA 0 0 0 0
Long-Term Debt 41 46 51 0 38
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities 0 0 0 0
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities 93 97 99 98 110
Shareholders Equity 5/31/2024 2/29/2024 11/30/2023 8/31/2023 5/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) 364 364 364 339 339
Capital Surplus 24 24 23 23 20
Retained Earnings -412 -413 -409 -404 -403
Other Equity 1 1 1 1 3
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity -23 -25 -21 -42 -42
Total Liabilities & Shareholder's Equity 70 72 78 57 69
Total Common Equity 99,976 -25 -21 -42 -42
Shares Outstanding 45.90 45.90 45.90 24.20 24.20
Book Value Per Share 2,178.12 -0.54 -0.45 -1.72 -1.72